CytomX医疗 CTMX 深 沪
等待开盘 02-04 09:30:00 美东时间
5.935
-0.155
-2.55%
华盛通- 最 高6.17
- 今 开6.12
- 成交量 59.63万股
- 最 低 5.82
- 昨 收 6.09
- 总市值 9.79亿
- 52周最高 6.17
- 市盈率 静 15.78
- 换手率 0.36%
- 52周最低 0.40
- 委 比 33.33%
- 总股本 1.65亿
- 历史最高 35.00
- 量 比 0.63
- 振 幅 5.75%
- 历史最低 0.40
- 每 手 1
- 风险率 1.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
Cardiff Oncology announced leadership changes amid its growth phase. CEO Mark Erlander and CFO James Levine have stepped down, with Dr. Mani Mohindru, a board member, appointed interim CEO. The company seeks permanent replacements for both roles. Cardiff's lead product, onvansertib, a PLK1 inhibitor, is in mid-stage trials for RAS-mutated colorectal cancer and being evaluated in other cancers. Dr. Mohindru brings extensive biotech experience and ...
01-27 12:00
美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
Piper Sandler Maintains Overweight on CytomX Therapeutics, Raises Price Target to $10
Piper Sandler analyst Joseph Catanzaro maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $6.5 to $10.
01-20 21:19
CytomX Therapeutics Announces CX-2051 Phase 1 Colorectal Cancer Expansion Data On Track For Q1 2026; Varseta-M Phase 1 Combination Study With Bevacizumab In Colorectal Cancer To Start In Q1 2026 With Initial Data Expected By H1 2027
- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 -- Varsetatug masetecan ("Varseta-M") Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1 2026
01-08 21:17
CytomX Therapeutics Announces Business Update and Company Milestones for 2026
CytomX Therapeutics announced its 2026 business update, highlighting key milestones. Varseta-M (CX-2051) Phase 1 colorectal cancer (CRC) expansion data is expected in Q1 2026. A Varseta-M combination study with bevacizumab in CRC will start in Q1 2026, with initial data by mid-2027. CX-801 Phase 1 combination data with KEYTRUDA in melanoma is anticipated by end-2026. CEO Sean McCarthy will present at the JP Morgan Healthcare Conference on January...
01-08 13:00
Birkenstock, Insmed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining aroun...
2025-12-18 21:04
CytomX Therapeutics to Present at Upcoming December Investor Conferences
CytomX Therapeutics announced that its management will participate in two investor conferences in December 2025: the 8th Annual Evercore Healthcare Conference on December 2 in Coral Gables, FL, and the Piper Sandler 37th Annual Healthcare Conference on December 4 in New York, NY. Both events will feature fireside chats and live webcasts available on CytomX’s website. The company, focused on developing conditionally activated biologics for oncolog...
2025-11-25 13:00
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference
CytomX Therapeutics' CEO, Sean McCarthy, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 20, 2025. A live webcast of the presentation will be available on CytomX's website, and management will also hold one-on-one meetings with registered investors. CytomX is focused on developing conditionally activated biologics for cancer treatment, utilizing its PROBODY® therapeutic platform to create lo...
2025-11-13 13:00
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
2025-11-12 11:43
CytomX Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.
CytomX Therapeutics shares are trading lower after the company reported worse-t...
2025-11-07 06:20
